Alto Neuroscience, Inc. ( (ANRO) ) has provided an update.
On March 17, 2025, Alto Neuroscience announced that two of its board members, Jeff (Po Yu) Chen, Ph.D., and Maha Radhakrishnan, M.D., will not stand for re-election at the 2025 Annual Meeting of Stockholders. This decision was not due to any disagreements with the company. Following their departure, the board will reduce its size from seven to five members. Additionally, Alto Neuroscience reported its full-year 2024 financial results and highlighted significant progress in its clinical trials, including favorable interim analysis outcomes for the ALTO-300 Phase 2b MDD trial and completion of enrollment for the ALTO-203 Phase 2 trial. The company maintains a strong cash position to support its operations and upcoming clinical study readouts.
More about Alto Neuroscience, Inc.
Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company focused on developing novel precision medicines for neuropsychiatric disorders. The company leverages a proprietary platform to evaluate brain-based biomarkers and has completed multiple clinical studies across its pipeline programs.
YTD Price Performance: -36.07%
Average Trading Volume: 299,494
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $77.67M
For an in-depth examination of ANRO stock, go to TipRanks’ Stock Analysis page.